tetano
Editor, Senior Moderator
Front Microbiol
. 2022 Apr 18;13:842232.
doi: 10.3389/fmicb.2022.842232. eCollection 2022.
Antibody and T Cell Immune Responses to SARS-CoV-2 Peptides in COVID-19 Convalescent Patients
Ekaterina Garanina[SUP] 1 [/SUP], Shaimaa Hamza[SUP] 1 [/SUP], Robert J Stott-Marshall[SUP] 2 [/SUP], Ekaterina Martynova[SUP] 1 [/SUP], Maria Markelova[SUP] 1 [/SUP], Yuriy Davidyuk[SUP] 1 [/SUP], Venera Shakirova[SUP] 3 [/SUP], Neha Kaushal[SUP] 4 [/SUP], Manoj Baranwal[SUP] 4 [/SUP], Ilsiyar M Khaertynova[SUP] 3 [/SUP], Albert Rizvanov[SUP] 1 [/SUP], Toshana L Foster[SUP] 2 [/SUP], Svetlana Khaiboullina[SUP] 1 [/SUP]
Affiliations
Abstract
Identifying immunogenic targets of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is critical to advance diagnostic and disease control strategies. We analyzed humoral (ELISA) and T-cell (ELISpot) immune responses to spike (S) and nucleocapsid (N) SARS-CoV-2 proteins as well as to human endemic coronavirus (eCoV) peptides in serum from convalescent coronavirus disease 2019 (COVID-19) patients from Tatarstan, Russia. We identified multiple SARS-CoV-2 peptides that were reactive with serum antibodies and T cells from convalescent COVID-19. In addition, age and gender associated differences in the reactivity to S and N protein peptides were identified. Moreover, several SARS-CoV-2 peptides tested negatively correlated with disease severity and lung damage. Cross-reactivity to eCoV peptides was analyzed and found to be lower in COVID-19 compared to controls. In this study, we demonstrate the changing pattern of immunogenic peptide reactivity in COVID-19 serum based on age, gender and previous exposure to eCoVs. These data highlight how humoral immune responses and cytotoxic T cell responses to some of these peptides could contribute to SARS-CoV-2 pathogenesis.
Keywords: COVID-19; SARS-CoV-2; antibody humoral immune response; peptides; spike protein.
. 2022 Apr 18;13:842232.
doi: 10.3389/fmicb.2022.842232. eCollection 2022.
Antibody and T Cell Immune Responses to SARS-CoV-2 Peptides in COVID-19 Convalescent Patients
Ekaterina Garanina[SUP] 1 [/SUP], Shaimaa Hamza[SUP] 1 [/SUP], Robert J Stott-Marshall[SUP] 2 [/SUP], Ekaterina Martynova[SUP] 1 [/SUP], Maria Markelova[SUP] 1 [/SUP], Yuriy Davidyuk[SUP] 1 [/SUP], Venera Shakirova[SUP] 3 [/SUP], Neha Kaushal[SUP] 4 [/SUP], Manoj Baranwal[SUP] 4 [/SUP], Ilsiyar M Khaertynova[SUP] 3 [/SUP], Albert Rizvanov[SUP] 1 [/SUP], Toshana L Foster[SUP] 2 [/SUP], Svetlana Khaiboullina[SUP] 1 [/SUP]
Affiliations
- PMID: 35509311
- PMCID: PMC9058163
- DOI: 10.3389/fmicb.2022.842232
Abstract
Identifying immunogenic targets of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is critical to advance diagnostic and disease control strategies. We analyzed humoral (ELISA) and T-cell (ELISpot) immune responses to spike (S) and nucleocapsid (N) SARS-CoV-2 proteins as well as to human endemic coronavirus (eCoV) peptides in serum from convalescent coronavirus disease 2019 (COVID-19) patients from Tatarstan, Russia. We identified multiple SARS-CoV-2 peptides that were reactive with serum antibodies and T cells from convalescent COVID-19. In addition, age and gender associated differences in the reactivity to S and N protein peptides were identified. Moreover, several SARS-CoV-2 peptides tested negatively correlated with disease severity and lung damage. Cross-reactivity to eCoV peptides was analyzed and found to be lower in COVID-19 compared to controls. In this study, we demonstrate the changing pattern of immunogenic peptide reactivity in COVID-19 serum based on age, gender and previous exposure to eCoVs. These data highlight how humoral immune responses and cytotoxic T cell responses to some of these peptides could contribute to SARS-CoV-2 pathogenesis.
Keywords: COVID-19; SARS-CoV-2; antibody humoral immune response; peptides; spike protein.